Innovent Shares Promising Phase 1 Results of IBI3003 for Myeloma Patients #China #Suzhou #Multiple_Myeloma #Innovent #IBI3003
@newsen.bsky.social
@newsen.bsky.socialInnovent Shares Promising Phase 1 Results of IBI3003 for Myeloma Patients #China #Suzhou #Multiple_Myeloma #Innovent #IBI3003
@newsen.bsky.socialLong-Term Remission Achieved with CARVYKTI® in Multiple Myeloma Patients: Study Shows 50% Rate After Five Years #USA #Johnson_&_Johnson #Multiple_Myeloma #CARVYKTI #Raritan
@newsen.bsky.socialNew Data on TECVAYLI® and DARZALEX FASPRO® Show Promising Long-term Outcomes for Multiple Myeloma Patients #USA #Multiple_Myeloma #DARZALEX_FASPRO #Raritan #TECVAYLI
@newsen.bsky.socialMedisights Unveils AI-Driven Real-Time Market Insights for Complex Diseases #USA #New_York #Multiple_Myeloma #AI_Market_Intelligence #Medisights
@newsen.bsky.socialMedisights Introduces Groundbreaking AI Technology for Rapid Market Intelligence in Multiple Myeloma Treatment #USA #New_York #AI_Technology #Multiple_Myeloma #Medisights
@newsen.bsky.socialAbbVie's Phase 3 CERVINO Trial Results Show Promising Efficacy of Etentamig in Multiple Myeloma Patients #United_States #Multiple_Myeloma #AbbVie #North_Chicago #Etentamig